KOD News and Press, Kodiak Sciences Inc From 02/03/22

Kodiak Sciences (NASDAQ:KOD) completed enrollment in its GLEAM and GLIMMER phase 3 trials of KSI-301 in patients with diabetic macular edema (DME). "We are very pleased to have completed enrollment in our GLEAM and GLIMMER pivotal trials, where we are studying KSI-301's potenti...

Kodiak Sciences Completes Enrollment in GLEAM and GLIMMER Phase 3 Clinical Trials of KSI-301 in Patients with Diabetic Macular Edema - Over 900 patients with diabetic macular edema enrolled worldwide PR Newswire PALO ALTO, Calif. , Feb. 3, 2022 /PRNewswire/ -...

JP Morgan has upgraded Kodiak Sciences (KOD -1.9%) to outperform from neutral following results from a pivotal study on wet AMD treatment KSI-301 and conversations with key opinion leaders (KOLs). However, the firm lowered its price target to $90 from $124 (~45% upside from yesterday's close)...

As per its latest filing, Kodiak Sciences' (KOD +6.3%) Director Baker Bros. Advisors, 10% owner, purchased 347,665 shares in multiple transactions for price ranging between $49.47 - $57.47 between the period Jan.27 to Jan.31, 2022. The transactions totaled to a value of ~$18.1M. Felix J. Bake...

Kodiak Sciences to Present at the 40th Annual J.P. Morgan Healthcare Conference PR Newswire PALO ALTO, Calif. , Jan. 3, 2022 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing t...

Kodiak Sciences Completes Enrollment in BEACON Phase 3 Clinical Trial of KSI-301 in Patients with Retinal Vein Occlusion − Over 550 patients with macular edema secondary to Retinal Vein Occlusion enrolled worldwide PR Newswire PALO ALTO, Calif. , Dec. 16...

Although the Healthcare sector is having a positive year in absolute terms, that isn't the case in relative terms. Biotech stocks are having a difficult year, in spite of many of those trading at dirt-cheap valuations that don't even reflect the cash they have in-hand. It's very l...

Kodiak Sciences (NASDAQ:KOD): Q3 GAAP EPS of -$1.30 misses by $0.11. Kodiak ended the third quarter of 2021 with $799.2 million of cash and cash equivalents. Press Release For further details see: Kodiak Sciences EPS misses by $0.11

Kodiak Sciences Announces Third Quarter 2021 Financial Results and Recent Business Highlights PR Newswire PALO ALTO, Calif. , Nov. 9, 2021 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing an...

Baker Brothers’ 13F portfolio value decreased from $23.07B to $22.77B this quarter. The InVitae stake was reduced this quarter while increasing Apellis Pharma and Heron Therapeutics. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almo...